First grade

Global Recycling Foundation announces Recycling Heroes & Young Green Ambassadors awards of Global Recycling Day 2024

Retrieved on: 
Monday, March 18, 2024
Friends, School, University, Clothing, Carbon, American School, Municipal solid waste, Policy, Paper, Equivalence, Woman, Recycling, Trachoma, Climate change, Organization, Plastic Bank, GHG, PEPC, Knowledge, Green Team, MD, Student, App Store (iOS/iPadOS), Plastic, Self-help group (finance), Book, Family, Movement, Pneumonia, Environment, First grade, Tata Steel, Collection

LONDON, March 18, 2024 /PRNewswire/ -- The Global Recycling Foundation today announces the ten winners of their Recycling Heroes 2024 award along with five special awards for Young Green Ambassadors marking the seventh Global Recycling Day on 18th March.

Key Points: 
  • LONDON, March 18, 2024 /PRNewswire/ -- The Global Recycling Foundation today announces the ten winners of their Recycling Heroes 2024 award along with five special awards for Young Green Ambassadors marking the seventh Global Recycling Day on 18th March.
  • Ranjit Baxi, Founding President of the Global Recycling Foundation, said: "This year's list of Recycling Heroes should be a cause for celebration.
  • Henry Green Primary School, Dagenham, London, UK for sustainability work in school led by Pupils in the Green team.
  • Otilo Foundation, Nigeria has significantly reduced carbon emissions by recycling approximately 65,000 metric kilograms of cartons and plastic waste from November 2023 to February 2024.

Global Recycling Foundation announces Recycling Heroes & Young Green Ambassadors awards of Global Recycling Day 2024

Retrieved on: 
Monday, March 18, 2024
Friends, School, University, Clothing, Carbon, American School, Municipal solid waste, Policy, Paper, Equivalence, Woman, Recycling, Trachoma, Climate change, Organization, Plastic Bank, GHG, PEPC, Knowledge, Green Team, MD, Student, App Store (iOS/iPadOS), Plastic, Self-help group (finance), Book, Family, Movement, Pneumonia, Environment, First grade, Tata Steel, Collection

LONDON, March 18, 2024 /PRNewswire/ -- The Global Recycling Foundation today announces the ten winners of their Recycling Heroes 2024 award along with five special awards for Young Green Ambassadors marking the seventh Global Recycling Day on 18th March.

Key Points: 
  • LONDON, March 18, 2024 /PRNewswire/ -- The Global Recycling Foundation today announces the ten winners of their Recycling Heroes 2024 award along with five special awards for Young Green Ambassadors marking the seventh Global Recycling Day on 18th March.
  • Ranjit Baxi, Founding President of the Global Recycling Foundation, said: "This year's list of Recycling Heroes should be a cause for celebration.
  • Henry Green Primary School, Dagenham, London, UK for sustainability work in school led by Pupils in the Green team.
  • Otilo Foundation, Nigeria has significantly reduced carbon emissions by recycling approximately 65,000 metric kilograms of cartons and plastic waste from November 2023 to February 2024.

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

Retrieved on: 
Wednesday, February 14, 2024
Investigational New Drug, Peripheral edema, Anemia, Gastroenteritis, Medicine, Periodic breathing, Leukopenia, Diarrhea, Quality of life, Cough, Dizziness, Deep vein thrombosis, Nausea, Vomiting, DVT, Common, Tremor, Back pain, Constipation, Safety, Dexamethasone, First grade, Lower respiratory tract infection, URTI, Bronchitis, Therapy, Fatigue, Bortezomib, Pharmacokinetics, Thrombocytopenia, Rash, Patient, Neutropenia, Acceleration, Multiple myeloma, RMOC, IND, Insomnia, Lenalidomide, Appetite, Abdominal pain, Weakness, Pharmaceutical industry

The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).

Key Points: 
  • The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).
  • Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
  • I’m excited about the potential opportunity STAR-LLD can bring to multiple myeloma patients.”
    Earlier last month, Starton disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.
  • Notably, no hematologic toxicities greater than Grade 1 have been observed following up to 3 cycles of treatment thus far.

The Ultimate Guide to Maximizing Your Fortune in Hong Kong

Retrieved on: 
Thursday, February 8, 2024
Hau Wong, Education, Happiness, Flower, Goddess, Tai Sui, Statue, History, Victoria Harbour, System, Element, Family, Chinese New Year, Health, Nature, Love, Burn, Risk, Student, Literature, Fertility, First grade, Copper, Sheung Wan, Water, Che Kung Miu, Peak Tram, Marriage, Wong Tai Sin Temple

With this “Ultimate Guide to a Prosperous Year of the Dragon” curated by feng shui master Mak Ling Ling, you can effortlessly unlock a perfect new year while immersed in the festive bliss around Hong Kong!

Key Points: 
  • With this “Ultimate Guide to a Prosperous Year of the Dragon” curated by feng shui master Mak Ling Ling, you can effortlessly unlock a perfect new year while immersed in the festive bliss around Hong Kong!
  • No Chinese New Year trip to Hong Kong is complete without a visit to the temple!
  • Among the numerous temples in Hong Kong dedicated to Kwun Yum, the one in Hung Hum is the largest and most famous in Kowloon.
  • Don’t miss out on the festivities and temple-hopping itineraries to usher in good fortune for the Year of the Dragon!

The Ultimate Guide to Maximizing Your Fortune in Hong Kong

Retrieved on: 
Friday, January 26, 2024
Tourist Attractions, Vacation, Other Travel, Destinations, Travel, Student, Family, Goddess, Chinese New Year, Fertility, Burn, Health, Sheung Wan, Marriage, Happiness, Tai Sui, History, Element, Flower, Risk, Hau Wong, Love, Peak Tram, Water, First grade, Che Kung Miu, System, Copper, Literature, Victoria Harbour, Wong Tai Sin Temple, Education, Statue

With this “Ultimate Guide to a Prosperous Year of the Dragon” curated by feng shui master Mak Ling Ling, you can effortlessly unlock a perfect new year while immersed in the festive bliss around Hong Kong!

Key Points: 
  • With this “Ultimate Guide to a Prosperous Year of the Dragon” curated by feng shui master Mak Ling Ling, you can effortlessly unlock a perfect new year while immersed in the festive bliss around Hong Kong!
  • View the full release here: https://www.businesswire.com/news/home/20240125477809/en/
    Pray for success in career and education in Man Mo Temple (Photo: Hong Kong Tourism Board)
    No Chinese New Year trip to Hong Kong is complete without a visit to the temple!
  • Among the numerous temples in Hong Kong dedicated to Kwun Yum, the one in Hung Hum is the largest and most famous in Kowloon.
  • Take action now for planning your trip to Hong Kong, don’t miss out on the festivities and temple-hopping itineraries to usher in good fortune for the Year of the Dragon!

New Curriculum Associates Research Shows Young Students Are Less Prepared for Grade-Level Learning in Reading and Mathematics

Retrieved on: 
Friday, January 12, 2024
Student, Learning, Research, Curriculum, First grade, Diagnosis, News, Education, Tutoring

NORTH BILLERICA, Mass., Jan. 12, 2024 /PRNewswire/ -- Curriculum Associates, a leading education technology company, released a new report today, School Readiness for Young Students Post-Pandemic, which includes the latest insights on student learning. The report examines nationwide data quantifying the latent academic impact of disrupted access to early childhood care and education for the nation's youngest learners. This report is one of the first to gather and analyze nationally representative data from more than five million Grades K–2 students, thanks to the company's i-Ready® Diagnostic for Reading and Mathematics.

Key Points: 
  • Students appear less prepared at school entry, with greater proportions of students entering below grade level.
  • These findings echo the emerging trends described in the latest edition of Curriculum Associates' State of Student Learning research .
  • School Readiness for Young Students Post-Pandemic is the seventh in a series of research reports on the effects of unfinished learning conducted by Curriculum Associates.
  • More information on Curriculum Associates' research on unfinished learning may be found here .

SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Regeneron Pharmaceuticals, Initiate, Conference, AACR, Orange Book, MAPK, Amgen, IND, B-cell maturation antigen, FDA, EMA, BeiGene, EGFR, MAA, Pain, Multiple myeloma, NDA, BCMA, Therapy, Cancer, Investigational New Drug, Event, First grade, Standard of care, TEAD, Neoplasm, Plantar fibromatosis, European Medicines Agency, RAF, European Hematology Association, CD3, MEK, Webcast, NRAS, RAS, Patient, Panitumumab, Pharmaceutical industry

Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024.

Key Points: 
  • Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024.
  • These presentations demonstrated rapid, sustained and consistent improvements in pain and functional status in patients receiving OGSIVEO using multiple assessment tools.
  • Initiate Phase 1 trial of SW-682, SpringWorks’ TEAD inhibitor, in Hippo mutant solid tumors in the first half of 2024.
  • A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN

Retrieved on: 
Thursday, November 16, 2023
NDA, Medicine, Vomiting, Disease, Safety, Food, Therapy, Rash, MEK, European Commission, Aes, First grade, Civil service commission, Patient, Solar cycle 24, FDA, New Drug Application, ORR, Diarrhea, Nausea, Cancer, Pain, Orphan drug, NF1, MRI, Quality of life, Fast Track, Sympathetic nervous system, Nursing, Pharmaceutical industry

The ReNeu trial enrolled 114 patients in two cohorts (pediatric and adult) across 50 sites in the U.S.

Key Points: 
  • The ReNeu trial enrolled 114 patients in two cohorts (pediatric and adult) across 50 sites in the U.S.
  • Mirdametinib was generally well tolerated in the ReNeu trial, with the majority of adverse events (AEs) being Grade 1 or Grade 2.
  • “We are extremely pleased that the results of our ReNeu trial demonstrate a compelling clinical profile across measures of both safety and efficacy.
  • SpringWorks plans to submit a New Drug Application (NDA) for mirdametinib to the FDA in the first half of 2024.

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, November 14, 2023
Sale, Associate, Translation, Research, Safety, Foreign investment, Food, Transaction, WM, First grade, CRS, IND, Disease, Glioblastoma, Risk, Waldenström macroglobulinemia, Clinical trial, GBM, Patient, CD19, Nature, FDA, Follicular lymphoma, University of Washington, Chronic lymphocytic leukemia, File, Mustang, Diagnosis, University, Mustang Bio, Cancer, Society, CFIUS, Letter, DSM-IV codes, Lymphoma, AACR, Cytokine release syndrome, Indolent lymphoma, Pharmaceutical industry, Cryptocurrency, Video game

WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023.

Key Points: 
  • WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023.
  • Subsequent to the end of the third quarter, Mustang raised approximately $4.4 million of gross proceeds in a registered direct offering completed in October 2023.
  • Research and development expenses were $9.5 million for the third quarter of 2023, compared to $15.5 million for the third quarter of 2022.
  • General and administrative expenses were $2.1 million for the third quarter of 2023, compared to $3.4 million for the third quarter of 2022.

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Pharmacokinetics, First grade, Bone marrow, Safety, CD73, Plasma, Half-life, Patient, Trae tha Truth, Fluoride toxicity, Pharmaceutical industry

The study included a heavily pretreated patient population where all patients were triple-class refractory, 88% were penta-refractory, and 59% also received prior anti-BCMA/CD3 bispecific therapy or anti-BCMA CAR-T therapy.

Key Points: 
  • The study included a heavily pretreated patient population where all patients were triple-class refractory, 88% were penta-refractory, and 59% also received prior anti-BCMA/CD3 bispecific therapy or anti-BCMA CAR-T therapy.
  • ORIC-533 demonstrated good bioavailability and a plasma half-life of ~24 hours.
  • Strong inhibition of soluble CD73 enzymatic activity was seen across all dose levels.
  • Overall, ORIC-533 demonstrated an acceptable safety profile and preliminary evidence of immune activation in this heavily pretreated patient population.